Security record · archived quarter
SANA
Sana Biotechnology, Inc. · Healthcare · Biotechnology
2Tracked holders
0Δ holders
49.50KShares held
$139,113Reported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 49.50K | $139,113 | n/a | n/a |
| Q2 2026 | 85 | +4 | 119.01M | $415.23M | +9 | −5 |
| Q1 2026 | 84 | -3 | 118.01M | $339.95M | +3 | −6 |
| Q4 2025 | 87 | +2 | 116.35M | $473.54M | +2 | n/a |
| Q3 2025 | 15 | -2 | 97.26M | $345.27M | n/a | −2 |
| Q2 2025 | 14 | 0 | 77.71M | $212.16M | +2 | −2 |
| Q1 2025 | 11 | -1 | 31.65M | $53.17M | +1 | −2 |
| Q4 2024 | 12 | -1 | 32.20M | $52.48M | +1 | −2 |
| Q3 2024 | 12 | +2 | 22.88M | $95.19M | +2 | n/a |
| Q2 2024 | 10 | n/a | 23.15M | $126.39M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 39.50K | -36.1% | $110,213 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | TD Waterhouse Canada Inc. | 10.00K | 0.0% | $28,900 | 0.0% | Held | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 199 holders, 163.30M shares, $468.43M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Aug 14
SC 13G/A: ARCH Venture Fund IX, L.P.
May 21
SC 13G: RA CAPITAL MANAGEMENT, L.P.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API